Tetracaine Eye Drops Should NOT Be Given to Patients for Welder's Flash
Tetracaine is indicated only for in-office diagnostic and procedural use under direct healthcare provider supervision and should never be prescribed for patient self-administration, including for welder's flash (photokeratitis). 1
Why Tetracaine is Inappropriate for Welder's Flash
FDA-Mandated Restrictions
The FDA label explicitly states that tetracaine is "not intended for patient self-administration" and must be administered "under the direct supervision of a healthcare provider" 1. This is a critical safety restriction that applies to all outpatient scenarios, including photokeratitis from welding exposure.
Serious Risk of Corneal Toxicity
Prolonged use or abuse of topical anesthetics leads to corneal epithelial toxicity, manifesting as epithelial defects that can progress to permanent corneal damage 1. This is particularly concerning because:
- Patients cannot feel ongoing corneal injury while using the anesthetic
- The drug masks symptoms that would normally prompt patients to seek care
- Accidental injuries occur due to corneal insensitivity for 10-20 minutes after each application 1
Real-World Evidence of Misuse
Research demonstrates that tetracaine misuse is a significant problem among welding workers. A 2014 study found that 30.5% of welders used topical anesthetics for occupational eye injuries, with misuse significantly associated with ocular complications including keratopathy and vision loss 2, 3. A 2026 study confirmed that tetracaine misuse was significantly more common among patients with prior history of use and was significantly associated with vision-threatening complications 3.
Appropriate Treatment for Welder's Flash
Immediate Management
For photokeratitis from welding exposure, the evidence-based approach includes:
- Topical broad-spectrum antibiotics to prevent secondary bacterial infection, as corneal abrasions from trauma (including UV exposure) require antibiotic prophylaxis 4
- Cycloplegic agents to reduce pain from ciliary spasm 4, 5
- Topical lubricants for symptomatic relief 6, 7
- Topical corticosteroids may be considered to control inflammation once infection is ruled out 6
Pain Management Strategy
While tetracaine provides effective analgesia, the risk-benefit analysis clearly favors alternative approaches:
- Oral analgesics (NSAIDs or acetaminophen) for systemic pain control
- Cycloplegics for pain reduction from anterior segment inflammation 4, 5
- Cool compresses and dark environment for symptomatic relief
- Lubricating drops/ointments for comfort
Clinical Course
Photokeratitis typically presents 6-12 hours after UV exposure with bilateral eye pain, photophobia, tearing, and foreign body sensation 7. Examination reveals punctate epithelial erosions with fluorescein staining 7. Complete recovery occurs within 7-10 days with appropriate supportive care 7.
Critical Pitfalls to Avoid
- Never prescribe tetracaine for home use - This violates FDA labeling and exposes patients to serious corneal complications
- Do not use bandage contact lenses with prophylactic antibiotics in trauma cases - This increases risk of secondary bacterial keratitis 4
- Avoid eye patching - Not recommended for corneal abrasions, particularly in trauma settings 4
- Monitor for secondary infection - Prophylactic antibiotics should be started within 24 hours of injury 4
When to Refer
Patients should be referred to ophthalmology if:
- Symptoms persist beyond 48 hours
- Vision does not improve
- Signs of infection develop (increased pain, purulent discharge, worsening redness)
- Central corneal involvement is present
The evidence overwhelmingly supports that while tetracaine provides effective analgesia in controlled settings 8, the risks of patient self-administration far outweigh any benefits, particularly given the availability of safer alternatives for managing photokeratitis pain.